Mesenchymal stem cells and organ transplantation: Current status and promising future

Transplantation

Volumn 81, Issue 10, 2006, Pages 1388-1389

  Bolaños Meade, Javier ^a   Vogelsang, Georgia B ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5' NUCLEOTIDASE; ACTIVATED LEUKOCYTE CELL ADHESION MOLECULE; BETA1 INTEGRIN; CD14 ANTIGEN; CD34 ANTIGEN; CD45 ANTIGEN; ENDOGLIN; GAMMA INTERFERON; HLA A1 ANTIGEN; MATRIX PROTEIN; THY 1 ANTIGEN; VASCULAR CELL ADHESION MOLECULE 1;

ACUTE GRAFT VERSUS HOST DISEASE; ADIPOSE TISSUE; ANTIGEN EXPRESSION; BONE MARROW CELL; CELL ISOLATION; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOMODULATION; IN VIVO CULTURE; INTERFERON PRODUCTION; MESENCHYMAL STEM CELL; MESENCHYMAL STEM CELL TRANSPLANTATION; NOTE; ORGAN TRANSPLANTATION; OSTEOARTHRITIS; OSTEOGENESIS IMPERFECTA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN SYNTHESIS; T CELL DEPLETION; TRANSPLANTATION TOLERANCE; UMBILICAL CORD BLOOD;

FORECASTING; GRAFT VS HOST DISEASE; HUMANS; IMMUNOTHERAPY; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STEM CELLS; ORGAN TRANSPLANTATION;

EID: 33744947299     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000214461.47555.70     Document Type: Note

References (12)

1. Väänänen HK. Mesenchymal stem cells. Ann Med 2005; 37: 469-479.
2. Le Blanc K, Ringdén O. Immunobiology of human mesenchymal stem cells and future use in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2005; 11: 321-334.
3. Beyth S, Borovsky Z, Mevorach D, et al. Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T-cell unresponsiveness. Blood 2005; 105: 2214-2219.
4. Le Blanc K, Tammik L, Sundberg B, et al. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand J Immunol 2003; 57: 11-20.
5. Rasmusson I, Ringdén O, Sundberg B, Le Blanc K. Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells. Transplantation 2003; 76: 1208-1213.
6. Di Nicola M, Carlo-Stella C, Magni M, et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 2002; 99: 3838-3843.
7. Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005; 105: 1815-1822.
8. Koc ON, Gerson SL, Cooper BW, et al. Rapid hematopoietic recovery after coinfusion of autologous-blood stem cells and culture-expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high-dose chemotherapy. J Clin Oncol 2000; 18: 307-316.
9. Lazarus HM, Koc ON, Devine SM, et al. Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients. Biol Blood Marrow Transplant 2005; 11: 389-398.
10. Lee ST, Jang JH, Cheong JW, et al. Treatment of high-risk acute myelogenous leukaemia by myeloablative chemoradiotherapy followed by co-infusion of T cell-depleted haematopoietic stem cells and culture-expanded marrow mesenchymal stem cells from a related donor with one fully mismatched human leucocyte antigen haplotype. Br J Haematol 2002; 118: 1128-1131.
11. Le Blanc K, Rasmusson I, Sundberg B, et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 2004; 363: 1439-1441.
12. Bolaños-Meade J, Vogelsang GB. Novel strategies for steroid-refractory acute graft-versus-host disease. Curr Opin Hematol 2005; 12: 40-44.